The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 07, 2022
Filed:
Oct. 12, 2018
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Université Paul Sabatier Toulouse Iii, Toulouse, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Klinikum Rechts Der Lsar Der Technischen Universität München, Munich, DE;
Julie Guillermet-Guibert, Toulouse, FR;
Maximillian Reichert, Munich, DE;
Célia Cintas, Toulouse, FR;
INSERM, Paris, FR;
Université Paul Sabatier Toulouse III, Toulouse, FR;
CNRS, Paris, FR;
Klinikum Rechts der Isar der Technischen Universität München, Munich, DE;
Abstract
PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. The inventors questioned this concept, by mapping differential isoform-specific downstream signalling in response to their constant selective inhibition in pancreatic cancer, a disease currently without therapy. They identified common and specific signals activated by each PI3K isoform. These data make the rational for the development of highly selective PI3K isoform drugs used in combination, instead of compounds inhibiting all PI3Ks. In particular, the inventors showed that combined p110a and 110γ inhibition is the most efficient strategy for pancreatic cancer patients.